Artios Pharma is a series c plus startup. 2 investors tracked.
Artios Pharma is a startup founded in 2015 based in the United Kingdom. Its most recent tracked round is Series-c-plus. Brouky records 3 investors associated with the company.
Artios Pharma is a clinical-stage biopharmaceutical company focused on developing DNA damage response (DDR)-based therapeutics for cancer treatment, specializing in small-molecule inhibitors targeting DDR pathways such as ATR and Pol Theta to treat challenging solid tumors.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.